Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is Absci Corporation (ABSI) Stock Up +8.84% Today?

Why Is Absci Corporation (ABSI) Stock Up +8.84% Today?

Key Takeaways

  • Absci Corporation (ABSI) is up 8.84% in Tuesday's session, trading at $8.25 versus the prior close of $7.58.
  • No new company release or filing drove the move; the primary catalyst is a sharp rebound after three consecutive losing sessions that had erased roughly 18% of the share price.
  • Secondary drivers include a scheduled fireside chat at the Jefferies Global Healthcare Conference and a wave of post-earnings Buy reiterations with targets of $14–$16.
  • Sentiment remains focused on December's 13-week interim HEADLINE data for ABS-201 in pattern hair loss, the company's binary near-term event.
  • News Significance Score: 20/100 — Minor scheduled-event news and analyst support drove a move only about 1.7x its typical session.
  • Traders are watching whether the bounce holds above the $8.00 area and whether volume expands into the December readout.
  • For deeper research, explore Price Targets, Earnings, and Forecast pages on Tickeron.
  • See which strategies are currently working by exploring Trending AI Robots.

Opening Summary

Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company that uses generative AI models paired with a high-throughput wet-lab engine to design antibodies and other biologics. Its lead asset, ABS-201, targets the prolactin receptor and is in a Phase 1/2a trial in pattern hair loss, with a second program planned in endometriosis. Shares are trading at $8.25, up $0.67 or 8.84% from the prior close of $7.58, after touching an intraday high of $8.73. The direction is unambiguously higher. No new fundamental disclosure explains the move; the advance is best characterized as a rebound and pre-data positioning move, reinforced by management's appearance at a major healthcare conference and firm sell-side support published after last week's quarterly report.

A Rebound After a Three-Session Slide

The most direct explanation is positioning. Absci fell 9.73% on November 12 after third-quarter partner revenue of $0.3 million fell well short of expectations of roughly $0.66 million, even though the $0.19 per-share loss matched consensus and cash of $173.7 million was confirmed as sufficient into the second half of 2028. The stock then dropped 7.50% and 11.54% in the following two sessions, bottoming at $7.29 on November 16. From the October 29 close of $12.10, shares had lost roughly 38% at the low.

That slide left the stock stretched well below its 50-day moving average, which sits near $9.66, and set up the kind of sharp countertrend bounce common in high-beta clinical biotech names. Absci's beta is above 2, and it has posted double-digit single-session moves repeatedly over the past quarter. Today's gain recovers only part of the recent decline.

December Data Remains the Real Catalyst

Nothing in today's tape is new information. Management reiterated the same roadmap it laid out with earnings: 13-week interim proof-of-concept data from the HEADLINE trial of ABS-201 in pattern hair loss are expected in December 2026, with full 26-week data in early 2027 and a Phase 2 STORYLINE trial in endometriosis planned for mid-2027. The company also recently appointed former Galderma executive Gerry Muhle as chief commercial officer, signaling preparation for a consumer-facing launch.

Bulls are using the drawdown to build exposure ahead of that readout, which management has framed as a test of whether the prolactin receptor mechanism drives measurable hair regrowth. Because the study remains blinded until 26 weeks, the December release is expected to be placebo-adjusted and partial by cohort, a structure that amplifies event risk in both directions.

Analyst Support and a Scheduled Conference Appearance

Post-earnings research has been constructive. BTIG reiterated a Buy rating with a $16 target, Needham raised its target to $15, and Guggenheim trimmed its target to $14 from $15 purely on a fully diluted share count while keeping a Buy rating. Consensus sits in the Buy/Strong Buy range across 12 analysts with targets spanning $10 to $20 — a spread that leaves ample room for disagreement about fair value.

Absci management is also holding a fireside chat today at 10:00 a.m. Eastern at the Jefferies Global Healthcare Conference in London. The appearance was announced on October 27 and contains no fresh financial disclosure, so it is a supportive backdrop rather than the trigger — buying was already evident in the opening minutes of the session.

Market Context and Trading Activity

The gain is company-specific rather than sector-driven. The iShares Biotechnology ETF was essentially flat and the broader XBI up only fractionally, while the S&P 500 slipped and small caps outperformed modestly. Absci's move is therefore many times larger than the industry backdrop.

Volume through the first hours of trading was moderate and clearly below the heavy 4.9 million to 7.9 million share sessions seen during last week's selloff, which is consistent with a short-covering and dip-buying bounce rather than institutional accumulation. Technically, the stock remains above its 200-day moving average near $6.78 but far below its 50-day line, and it is still roughly 34% below its 52-week high of $12.55. Market capitalization is about $1.4 billion.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Absci lands at 20 out of 100.

The news component is weak: no new release, filing, or data readout exists, and a scheduled conference appearance plus reiterations and a technical target cut are routine events for a name this size. The price component is also modest. At 8.84%, the move is about 1.7 times the stock's average absolute daily change of roughly 5.2%, and moves of this size or larger occurred 16 times across the last 60 sessions. Both factors are muted, which produces a low combined score.

What Comes Next for ABSI

The near-term agenda is dominated by the December 13-week interim HEADLINE results for ABS-201, followed by full 26-week data in early 2027 and a planned Phase 2 endometriosis trial in mid-2027. Management is expected to detail commercial strategy and pricing assumptions at the Evercore Healthcare Conference on December 1. No further earnings release is scheduled until fourth-quarter results in early 2027.

Key risks include dilution to fund a widening loss, which reached $33.3 million last quarter, and the possibility that interim efficacy falls short of the roughly 15 hairs-per-square-centimeter placebo-adjusted bar the trial is powered to detect. Because the stock is valued almost entirely on ABS-201's probability of success, sentiment can reverse quickly if pre-data enthusiasm outruns the evidence.

Trending AI Robots

Tickeron's Trending AI Robots page curates a live view of its automated trading systems, drawing from hundreds of AI bots that cover thousands of tickers. Only the strongest performers under current market conditions earn a place in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the roster shifts as volatility and leadership change. Visitors can compare approaches side by side and identify which strategies are adapting best to present conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ABSI

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


ABSI in downward trend: 10-day moving average moved below 50-day moving average on November 16, 2026

The 10-day moving average for ABSI crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABSI as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

ABSI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 241 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

ABSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 142 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.091) is normal, around the industry mean (3.592). P/E Ratio (-12.873) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
18105 SE Mill Plain Boulevard
Phone
+1 360 949-1041
Employees
140
Web
https://www.absci.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.